Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
University of Arizona
M.D. Anderson Cancer Center
University of Miami
Thomas Jefferson University
Thomas Jefferson University
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Thomas Jefferson University
City of Hope Medical Center
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
University of Cologne
Roswell Park Cancer Institute
University College, London
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Baylor College of Medicine
Martin-Luther-Universität Halle-Wittenberg
University of Nebraska
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Birmingham
St. Jude Children's Research Hospital
Northside Hospital, Inc.
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Thomas Jefferson University
University of Liege
University of Alabama at Birmingham
Northwell Health
H. Lee Moffitt Cancer Center and Research Institute
The Lymphoma Academic Research Organisation
Alliance for Clinical Trials in Oncology
Icahn School of Medicine at Mount Sinai
Masonic Cancer Center, University of Minnesota